The lower level of BLNK, CD40 and CD210 expression in patients with untreated MS likely influences the function of various B‐cell subsets, including IgA+CD20+ and IgG2+ B cells in controlling disease. The gene discussed is CD79A; the disease is myeloid sarcoma.